Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 4:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 849 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Benzodiazepine Clear all

Conditions: Multiple Sclerosis Fatigue
Interventions: Ketamine, Midazolam; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Malignant Neoplasm, Acute Myeloid Leukemia, Mixed Lineage Leukemia, Mixed Lineage Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia, Acute Lymphoblastic Leukemia
Interventions: Ziftomenib, Midazolam, Itraconazole; Drug
Lead sponsor: Kura Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 263 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 20
States / cities: Gilbert, Arizona • Los Angeles, California • Jacksonville, Florida + 16 more

Conditions: Panic Disorder
Interventions: Clonazepam, Sertraline, Cognitive behavioral therapy; Drug · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Solid Tumor
Interventions: SAR302503, omeprazol, metoprolol, midazolam; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Augusta, Georgia • Detroit, Michigan • Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Lanabecestat, Simvastatin, Midazolam, Donepezil; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Surgery, Sedation
Interventions: Triazolam, Midazolam, Microcrystalline Cellulose, Sodium chloride 0.9%; Drug
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Apathy, Schizophrenia, Schizophrenia; Psychosis
Interventions: Lumateperone 42 mg, Risperidone 2 mg; Drug
Lead sponsor: Louisiana State University Health Sciences Center Shreveport; Other
Eligibility: 18 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Bipolar Disorder
Interventions: olanzapine, risperidone; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 21
States / cities: Berkley, California • Los Angeles, California • Orange, California + 18 more

Conditions: Seizures
Interventions: Midazolam; Drug
Lead sponsor: U.S. Army Office of the Surgeon General; Federal
Eligibility: 18 Years to 54 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Schizophrenia
Interventions: bitopertin [RO4917838], olanzapine, placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 19
States / cities: Little Rock, Arkansas • Cerritos, California • Oceanside, California + 16 more

Conditions: Neoplasm Metastasis
Interventions: Drug Cocktail, Abemaciclib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 5
States / cities: Denver, Colorado • Indianapolis, Indiana • Fairway, Kansas + 2 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: BMS-214662, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Drug Interactions
Interventions: Telotristat etiprate, Midazolam; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Post-traumatic Stress Disorder, Generalized Anxiety Disorder, Panic Disorder, Social Anxiety Disorder
Interventions: Cognitive-behavioral therapy, Psychotropic medication optimization, Treatment as Usual; Behavioral · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 75 Years
Enrollment: 1,004 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 4
States / cities: Little Rock, Arkansas • La Jolla, California • Los Angeles, California + 1 more

Conditions: Schizophrenia
Interventions: TV-44749, Oral olanzapine; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 6
States / cities: Los Alamitos, California • Torrance, California • Hollywood, Florida + 3 more

Conditions: Succinic Semialdehyde Dehydrogenase Deficiency, SSADH Deficiency
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 5 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Psychotic Depression
Interventions: Sertraline + Olanzapine, Sertraline + Placebo; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 3
States / cities: Worcester, Massachusetts • White Plains, New York • Pittsburgh, Pennsylvania

Conditions: Pediatric Emergence Agitation and Pain
Interventions: Midazolam, Game Boy; Drug · Device
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 4 Years to 12 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Solid Tumor
Interventions: cobimetinib, dextromethorphan, midazolam; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 4
States / cities: Los Angeles, California • Stanford, California • Detroit, Michigan + 1 more

Conditions: Atherosclerosis, Healthy
Interventions: [C-11]PBR28; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 89 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Solid Tumours
Interventions: CYP1A2 (caffeine), CYP2C19 (omeprazole), CYP3A (midazolam), Kytril (granisetron), Wee-1 kinase inhibitor AZD1775; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more

Conditions: Endoscopic Ultrasound (EUS), Endoscopic Retrograde Cholangiopancreatography (ERCP)
Interventions: Meperidine, Midazolam, Diphenhydramine, Promethazine; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 304 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Orange, California

Conditions: Healthy Volunteers
Interventions: ALKS 3831, Olanzapine, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Healthy Volunteers Sickle Cell Disease, Thalassemia
Interventions: Etavopivat, Digoxin, Pitavastatin, Metformin, Midazolam, Rosuvastatin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Search by objective public record fields.

Ketamine for Multiple Sclerosis Fatigue

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Therapies for Treatment-Resistant Panic Disorder Symptoms

Drug Interaction Study of SAR302503 in Patients With Solid Tumor

A Drug-Drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants

Oral Versus Intravenous Sedation for Ocular Procedures

Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.

Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder

Phase I Trail for Intramuscular Administration of Midazolam Using An Autoinjector

A Study of RO4917838 (Bitopertin) in Patients With Acute Exacerbation of Schizophrenia

A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

BMS-214662 in Treating Patients With Solid Tumors

A Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Midazolam in Healthy Subjects

Primary Care Intervention Strategy for Anxiety Disorders

An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia

PET Imaging of GABA Receptors in Succinic Semialdehyde Dehydrogenase Deficiency

Sustaining Remission of Psychotic Depression

Does Distraction With a Hand Held Video Game Reduce Preoperative and Emergence Anxiety in Children?

Study of Cobimetinib in Participants With Solid Tumors

PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Carotid Atherosclerosis

Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

Adjunct Sedatives in Endoscopic Ultrasound (EUS) and Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures

An Insulin Sensitivity Study in Healthy Subjects

A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants